Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Gedske Daugaard Cora Sternberg Fabio Calabrò John Graham |
| Publication date | March 17, 2009 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |